Anne Frey Luetkemeyer MD
Assistant Professor, Medicine, UCSF School of Medicine
Join to View Full Profile
995 Potrero AveBox 0874San Francisco, CA 94110
Phone+1 415-476-4082
Fax+1 415-476-6953
Dr. Luetkemeyer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Fellowship, Infectious Disease, 2003 - 2006- University of California (San Francisco)Residency, Internal Medicine, 1999 - 2002
Harvard Medical SchoolClass of 1999
Certifications & Licensure
CA State Medical License 2001 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection Start of enrollment: 2008 Apr 01
- A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C Start of enrollment: 2014 Aug 01
- Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men Start of enrollment: 2019 Nov 26
Publications & Presentations
PubMed
- Hepatitis B virus vaccination in people with HIV: what's new?Fiona Gispen, Anne F Luetkemeyer, Kristen M Marks
Current Opinion in HIV and AIDS. 2025-12-08 - "It's Been a Very Liberating Experience": Doxycycline Postexposure Prophylaxis for Sexually Transmitted Infection Prevention and Experiences With Sexual Pleasure by Me...Rodney Perkins, Rob J Fredericksen, Katerina A Christopoulos, Kristin Beima-Sofie, Stephanie E Cohen
Sexually Transmitted Diseases. 2025-12-01 - 3 citationsEfficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study.Onyema Ogbuagu, Jason D Goldman, Robert L Gottlieb, Upinder Singh, Masaharu Shinkai
The Lancet. Infectious Diseases. 2025-12-01
Press Mentions
Antibiotic Cuts Risk of HIV, STDs After Exposure, Study SaysMay 8th, 2023- Doxy-PEP for STIs and More: Dr. Dieffenbach’s Highlights from Day 1 of CROI 2023February 21st, 2023
- Meta-Analysis Supports COVID-19 Mortality Benefit with IL-6 InhibitorsJuly 15th, 2021
Grant Support
- The Doxy-PEP Impact Study: a multi-city US longitudinal cohort to evaluate doxy-PEP field effectiveness, investigate associated antimicrobial resistance, and establish doxy-PEP to need ratiosUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2029
- Evaluation of doxycycline post-exposure prophylaxis to reduce sexually transmitted infections in PrEP users and HIV-infected men who have sex with menUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2019–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
